Target detail
ABO
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase
Data: Live structured evidence (Supabase)
Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).
Display name: ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase
Aliases: ABO, ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase
Type / organism: protein_coding · Homo sapiens
Source: opentargets · ENSG00000175164
Index freshness: last_synced_at 2026-05-15T17:45:14.374+00:00 · updated 2026-05-15T17:45:14.761466+00:00
Limitations & build flags
- Read-only structured navigator
- No clinical outcome benefit inferred
- Trial presence does not imply success
- Drug identity may require normalization
- Terminated/withdrawn trials must remain visible
This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.
Connectors represented in loaded rows for ABO. Empty groups mean no matching rows — not a claim about biology or clinical use.
- ClinicalTrials.govLive when indexed
Registry mirror rows in clinical_trials when operators run the CT.gov enrichment CLI — browser never calls the registry directly.
- Open TargetsLive when indexed
Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).
- ChEMBLLive when indexed
Drug–target and related enrichment rows when operators run enrich:chembl (server/CLI only).
Rows from disease_target_evidence for this symbol.
glioblastoma
literature · opentargets
Drug records tied via drug_targets — mechanistic linkage only.
disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.
No matching rows
Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.
Mirror rows whose text fields mention this symbol — registry context only.
NCT00979862 — Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT06059690 — Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT00255671 — Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00624728 — Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02179086 — Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov
Open trials hubNCT02661282 — Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02311920 — Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT07387666 — Imaging Acetadote Metabolism in Glioblastoma
Status: NOT_YET_RECRUITING · clinicaltrials.gov
Open trials hubNCT01222221 — Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT01009307 — Study of Blood and Cheek Cell Samples From Patients With Glioma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02658981 — Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT01782976 — Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
Status: WITHDRAWN · clinicaltrials.gov
Open trials hubNCT00884741 — Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02444546 — Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00253669 — Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00095940 — Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
Status: COMPLETED · clinicaltrials.gov
Open trials hubRepurposing signal rows for drugs linked to this target via drug_targets.
No research signals for linked drugs
Run the deterministic signal builder after drug_targets and source rows are present.
Structured rows with negative evidence_direction on disease–drug or signal tables.
No negative-direction rows
When structured evidence includes explicit negative direction fields, they surface here for oncology review.
- clinicaltrials.gov: 16
- chembl: 4
- opentargets: 1
Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.
Disease contexts
0
Linked drugs
0
Linked in dataset
0
Research signals
0
Doctor-discussion candidate and related tags are descriptive only.
Signals list: Live structured evidence (Supabase)
No matching live evidence found
When repurposing_signal rows reference this marker via linked drugs, summaries appear here.